Interim Results for the six months ended 31 December 2021
March 03, 2022 07:00 ET
|
Allergy Therapeutics
Allergy Therapeutics plc(“Allergy Therapeutics” or the “Company” or the “Group”) Interim Results for the six months ended 31 December 2021 ~ US readiness plan underway including two...
Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut
January 26, 2022 07:00 ET
|
Allergy Therapeutics
Allergy Therapeutics plc(“Allergy Therapeutics”, “ATL” or the “Group”) Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut Paves...
Allergy Therapeutics announces positive top line results from G309 exploratory field trial to evaluate efficacy and safety of Grass MATA MPL
October 25, 2021 07:00 ET
|
Allergy Therapeutics
Allergy Therapeutics plc(“Allergy Therapeutics”, “ATL” or the “Group”) Allergy Therapeutics announces positive top line results from G309 exploratory field trial to evaluate efficacy and safety...
Preliminary Results for the Year ended 30 June 2021
September 23, 2021 07:00 ET
|
Allergy Therapeutics
Allergy Therapeutics plc(“Allergy Therapeutics”, “ATL” or the “Group”) Preliminary Results for the Year ended 30 June 2021 Record pre-R&D operating profit ahead of market expectations...
Trading update
June 24, 2021 07:00 ET
|
Allergy Therapeutics
Allergy Therapeutics plc (“Allergy Therapeutics”, “ATL” or the “Group”) Trading update Operating profit strong and expected to be well ahead of market expectationsExpenses for 2021 significantly...
Allergy Therapeutics plc Preliminary Results for the year ended 30 June 2020
September 23, 2020 07:00 ET
|
Allergy Therapeutics
Allergy Therapeutics plc (“Allergy Therapeutics”, “ATL” or the “Group”) Preliminary Results for the year ended 30 June 2020 Record level of pre R&D operating profit supported by robust sales...
Allergy Therapeutics secures virus-like particle (“VLP”) technology platform to broaden vaccine pipeline through licensing agreements with Saiba AG and DeepVax GmbH
September 03, 2020 07:00 ET
|
Allergy Therapeutics
Allergy Therapeutics plc (“Allergy Therapeutics”, “ATL” or the “Group”), Saiba AG(“Saiba”) and DeepVax GmbH (“DeepVax”) Allergy Therapeutics secures virus-like particle (“VLP”) technology platform to...
Allergy Therapeutics Interim Results for the six months ended 31 December 2019
March 04, 2020 07:00 ET
|
Allergy Therapeutics
Allergy Therapeutics plc(“Allergy Therapeutics”, “ATL” or the “Group”)Interim Results for the six months ended 31 December 2019 Record level of operating profit pre R&D supported by strong...
Allergy Therapeutics plc - Successful litigation settlement relating to PQ Grass Phase II Trial
June 27, 2019 10:47 ET
|
Allergy Therapeutics
Allergy Therapeutics plc(“Allergy Therapeutics”, “ATL” or the “Group”) Successful litigation settlement relating to PQ Grass Phase II Trial 27 June 2019 Allergy Therapeutics plc (AIM: AGY), the...
Allergy Therapeutics plc - Trading Update and Successful Litigation Settlement
June 27, 2019 10:26 ET
|
Allergy Therapeutics
Allergy Therapeutics plc(“Allergy Therapeutics” or the “Group”) Trading Update and Successful Litigation Settlement 2019 full year earnings expected to be ahead of market expectations 27 June...